Subsequent double-blind randomized trials with intravenous naloxone showed modulation of secondary symptoms of pruritus in patients with liver cirrhosis.
Estudios subsecuentes doble ciegos, aleatorizados con naloxona intravenosa, modularon los síntomas secundarios a prurito en pacientes con cirrosis hepática.